Compare LFVN & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | LONA |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 76.8M |
| IPO Year | 1996 | N/A |
| Metric | LFVN | LONA |
|---|---|---|
| Price | $6.69 | $9.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | $10.00 |
| AVG Volume (30 Days) | ★ 851.7K | 12.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.17 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $4.21 |
| 52 Week High | $15.00 | $14.21 |
| Indicator | LFVN | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 60.08 |
| Support Level | $5.67 | $7.94 |
| Resistance Level | $11.71 | $9.62 |
| Average True Range (ATR) | 1.22 | 0.58 |
| MACD | -0.31 | 0.12 |
| Stochastic Oscillator | 19.16 | 90.26 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.